WallStreetZenWallStreetZen

NASDAQ: MTP
Midatech Pharma PLC Stock

$0.36+0.03 (+9.09%)
Updated Mar 21, 2023
MTP Price
$0.36
Fair Value Price
$2.61
Market Cap
$1.42M
52 Week Low
$0.33
52 Week High
$5.25
P/E
-0.42x
P/B
0.17x
P/S
18.63x
PEG
N/A
Dividend Yield
N/A
Revenue
$531.82k
Earnings
-$3.73M
Gross Margin
100%
Operating Margin
-720.94%
Profit Margin
-654.1%
Debt to Equity
0.29
Operating Cash Flow
-$9M
Beta
0.61
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

MTP Overview

Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MTP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

MTP ($0.36) is undervalued by 86.2% relative to our estimate of its Fair Value price of $2.61 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
MTP ($0.36) is significantly undervalued by 86.2% relative to our estimate of its Fair Value price of $2.61 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
MTP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MTP due diligence checks available for Premium users.

Be the first to know about important MTP news, forecast changes, insider trades & much more!

MTP News

Valuation

MTP fair value

Fair Value of MTP stock based on Discounted Cash Flow (DCF)
Price
$0.36
Fair Value
$2.61
Undervalued by
86.20%
MTP ($0.36) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MTP ($0.36) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MTP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

MTP price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.42x
Industry
16.62x
Market
22.45x

MTP price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.17x
Industry
4.85x
MTP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

MTP's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
MTP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MTP's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$11.8M
Liabilities
$2.7M
Debt to equity
0.29
MTP's short-term assets ($9.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MTP's short-term assets ($9.87M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MTP's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MTP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
MTP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

MTP vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
MTP$1.42M+9.09%-0.42x0.17x
TENX$1.42M+13.21%-0.09x0.36x
CNSP$1.47M+0.92%-0.10x0.17x
ENSC$1.56M-2.14%-0.03x-0.26x
CYTO$1.22M+2.14%-0.05x0.15x

Midatech Pharma Stock FAQ

What is Midatech Pharma's quote symbol?

NASDAQ: MTP) Midatech Pharma trades on the NASDAQ under the ticker symbol MTP. Midatech Pharma stock quotes can also be displayed as NASDAQ: MTP.

If you're new to stock investing, here's how to buy Midatech Pharma stock.

What is the 52 week high and low for Midatech Pharma (NASDAQ: MTP)?

(NASDAQ: MTP) Midatech Pharma's 52-week high was $5.25, and its 52-week low was $0.33. It is currently -93.14% from its 52-week high and 9.09% from its 52-week low.

How much is Midatech Pharma stock worth today?

(NASDAQ: MTP) Midatech Pharma currently has 98,493,413 outstanding shares. With Midatech Pharma stock trading at $0.36 per share, the total value of Midatech Pharma stock (market capitalization) is $1.42M.

Midatech Pharma stock was originally listed at a price of $1,837.50 in Dec 7, 2015. If you had invested in Midatech Pharma stock at $1,837.50, your return over the last 7 years would have been -99.98%, for an annualized return of -70.47% (not including any dividends or dividend reinvestments).

How much is Midatech Pharma's stock price per share?

(NASDAQ: MTP) Midatech Pharma stock price per share is $0.36 today (as of Mar 21, 2023).

What is Midatech Pharma's Market Cap?

(NASDAQ: MTP) Midatech Pharma's market cap is $1.42M, as of Mar 22, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Midatech Pharma's market cap is calculated by multiplying MTP's current stock price of $0.36 by MTP's total outstanding shares of 98,493,413.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.